Table 4 Univariate analysis for PFS2/PFS1 ratio ≥ 1.3 in treated patients with AGA
Characteristics | PFS2/PFS1 | p valuesa | ||
|---|---|---|---|---|
N | < 1.3 (N = 158) | ≥ 1.3 (N = 58) | ||
Age at inclusion, years | ||||
Median (range) | 216 | 57 (30–83) | 61 (22–79) | 0.426 |
Sex | 0.583 | |||
Male | 47 | 36 (23%) | 11 (19%) | |
Female | 169 | 122 (77%) | 47 (81%) | |
ECOG performance status at inclusion | 0.179 | |||
0 | 72 | 49 (36%) | 23 (48%) | |
1 | 88 | 66 (49%) | 22 (46%) | |
2 | 23 | 20 (15%) | 3 (6%) | |
Missing | 33 | |||
Cancer type | 0.869 | |||
Breast | 111 | 80 (51%) | 31 (53%) | |
Lung | 16 | 12 (8%) | 4 (7%) | |
Prostate | 14 | 8 (5%) | 6 (10%) | |
Ovary | 16 | 10 (6%) | 6 (10%) | |
Pancreas | 4 | 3 (2%) | 1 (2%) | |
Colorectal | 11 | 10 (6%) | 1 (2%) | |
Sarcoma | 6 | 5 (3%) | 1 (2%) | |
Endometrial | 5 | 3 (2%) | 2 (3%) | |
Uterine cervix | 6 | 4 (3%) | 2 (3%) | |
Liver-biliary tractus | 6 | 5 (3%) | 1 (2%) | |
Bladder-ureter | 4 | 4 (3%) | 0 (0%) | |
Kidney | 3 | 3 (2%) | 0 (0%) | |
CUP | 4 | 3 (2%) | 1 (2%) | |
Other | 10 | 8 (5%) | 2 (3%) | |
Pathological type | 1.000 | |||
Carcinoma | 206 | 149 (94%) | 57 (98%) | |
Sarcoma | 6 | 5 (3%) | 1 (2%) | |
Melanoma | 2 | 2 (1%) | 0 (0%) | |
Germinal tumor | 2 | 2 (1%) | 0 (0%) | |
Extension stage at inclusion | 0.450 | |||
Metastatic | 205 | 149 (95%) | 56 (98%) | |
Locally advanced | 9 | 8 (5%) | 1 (2%) | |
Missing | 2 | |||
Number of metastatic sites | ||||
Median (range) | 216 | 2 (0–6) | 2 (0–7) | 0.568 |
Number of previous lines of chemotherapy for advanced disease | ||||
Median (range) | 185 | 3 (1–12) | 3 (1–12) | 0.671 |
Missing | 31 | |||
Type of therapy | 1.30E−02 | |||
Matched | 89 | 57 (36%) | 32 (55%) | |
Non-matched | 127 | 101 (64%) | 26 (45%) | |